Division of Hepato‐Biliary‐Pancreatic Surgery and Transplantation, Department of Surgery, Graduate School of Medicine Kyoto University Kyoto Japan
Department of Surgery Kyoto City Hospital Kyoto Japan
Department of Cardiovascular Surgery, Graduate School of Medicine Kyoto University Kyoto Japan
Budd–Chiari syndrome (BCS) is a refractory veno-occlusive disease involving hepatic veins (HV) and/or inferior vena cava (IVC).1 Unlike in the West, hepatic IVC is characteristically involved in most BCS patients in the Asia-Pacific region, for example, 93% in Japan2 where ironically 90% of liver transplants (LT) are living-donor liver transplantation (LDLT). In deceased-donor LT, HV/IVC lesions in a patient can be totally replaced with a donor's healthy HV/IVC, but not by LDLT, leaving an unresolved dilemma of how to reconstruct HV/IVC in BCS-LDLT.
Conventionally, cavo-plasty, patch-plasty, or artificial graft replacement have been performed; however, once BCS lesions recur, patient mortality remains high.3-5 To prevent BCS recurrence, therefore, we developed a new technique for venous outflow reconstruction in LDLT. Briefly, the congested liver is excised with hepatic cava under veno-venous (VV)-bypass assistance (Figure 1a). On a back-table, hepatic IVC is isolated and scrutinized from not only outside but also inside the vessel under good direct view (Figures 1b,c and 2c; Video S1). After resecting the lesion, only the healthy portion is harvested; reversed the cranio-caudal ends for extra safety (Figure 1c,d); and the originally-caudal end of the auto-cava, that is, the part farthest from BCS lesions, is anastomosed to the intrapericardial IVC root or directly to the right atrium if the IVC root is affected. The remaining gap of IVC is interposed with an artificial graft, if necessary (Figure 2d,e). Then HV is anastomosed to the healthy auto-cava end-to-side. We can thus create the hepatic venous outflow using only healthy blood vessels, thereby minimizing the potential risk of BCS recurrence.
We have performed this procedure in the current four BCS-LDLT patients with 0% disease recurrence and 100% patient survival. Our novel strategy, en bloc excision of the liver with hepatic cava; ex vivo harvest of the healthy part of auto-cava; and its auto-transplant venous/caval reconstruction, appears safe and feasible for BCS-LDLT.